Abstract:Pulmonary arterial hypertension (PAH) is a life-threatening disease featured with elevated pulmonary vascular resistance and progressive pulmonary vascular remodelling. It has been demonstrated that lncRNA PAXIP1-AS1 could influence the transcriptome in PAH. However, the exact molecular mechanism of PAXIP1-AS1 in PAH pathogenesis remains largely unknown. In this study, in vivo rat PAH model was established by monocrotaline (MCT) induction and hypoxia was used to induce in vitro PAH model using human pulmonary artery smooth muscle cells (hPASMCs). Histological examinations including H&E, Masson's trichrome staining and immunohistochemistry were subjected to evaluate the pathological changes of lung tissues. Expression patterns of PAXIP1-AS1 and RhoA were assessed using qRT-PCR and Western blotting, respectively. CCK-8, BrdU assay and immunofluorescence of Ki67 were performed to measure the cell proliferation. Wound healing and transwell assays were employed to evaluate the capacity of cell migration. Dual-luciferase reporter assay, co-immunoprecipitation, RIP and CHIP assays were employed to verify the PAXIP1-AS1/ETS1/WIPF1/RhoA regulatory network. It was found that the expression of PAXIP1-AS1 and RhoA was remarkably higher in both lung tissues and serum of MCT-induced PAH rats, as well as in hypoxia-induced hPASMCs. PAXIP1-AS1 knockdown remarkably suppressed hypoxia-induced cell viability and migration of hPASMCs. PAXIP1-AS1 positively regulated WIPF1 via recruiting transcriptional factor ETS1, of which knockdown reversed PAXIP1-AS1-mediated biological functions. Co-immunoprecipitation validated the WIPF1/RhoA interaction. In vivo experiments further revealed the role of PAXIP1-AS1 in PAH pathogenesis. In summary, lncRNA PAXIP1-AS1 promoted cell viability and migration of hPASMCs via ETS1/WIPF1/RhoA, which might provide a potential therapeutic target for PAH treatment.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role of long - non - coding RNA (lncRNA) PAXIP1 - AS1 in the pathological process of pulmonary arterial hypertension (PAH) and its molecular mechanism. Specifically, the researchers hope to experimentally verify whether PAXIP1 - AS1 promotes the development of PAH through the ETS1/WIPF1/RhoA signaling axis and explore how this mechanism affects the proliferation and migration abilities of human pulmonary artery smooth muscle cells (hPASMCs). In addition, the study also aims to evaluate the potential of PAXIP1 - AS1 as a therapeutic target for PAH. ### Main research contents: 1. **Expression of PAXIP1 - AS1 and RhoA in PAH models**: - The researchers first established a rat PAH model induced by unilateral nephrectomy plus carbon tetrachloride (MCT). They evaluated the expression of PAXIP1 - AS1 and RhoA in the PAH model by detecting right ventricular systolic pressure (RVSP), histological staining (H&E and Masson's trichrome staining), and immunohistochemistry (IHC). - The results showed that, compared with the control group, the expressions of PAXIP1 - AS1 and RhoA in the PAH model were significantly increased. 2. **Effect of PAXIP1 - AS1 on the proliferation and migration of hPASMCs**: - By establishing an in vitro model of hPASMCs under hypoxic conditions, the researchers found that the expression of PAXIP1 - AS1 gradually increased under hypoxic conditions. - After knocking down PAXIP1 - AS1, the proliferation and migration abilities of hPASMCs were significantly decreased, indicating that PAXIP1 - AS1 plays a crucial role in the pathological process of PAH. 3. **PAXIP1 - AS1 positively regulates the expression of WIPF1 through the ETS1/WIPF1 axis**: - The researchers further explored the relationship between PAXIP1 - AS1 and ETS1/WIPF1 and found that PAXIP1 - AS1 positively regulates the expression of WIPF1 by recruiting the transcription factor ETS1. - Through experimental methods such as RIP, dual - luciferase reporter gene, and ChIP, the direct binding relationship between PAXIP1 - AS1 and ETS1 and its regulatory effect on the expression of WIPF1 were verified. 4. **Interaction between WIPF1 and RhoA**: - The researchers found that there is an interaction between WIPF1 and RhoA, and WIPF1 can regulate the expression of RhoA through post - translational modification of proteins. - Further experiments proved that inhibiting WIPF1 can reduce the protein level of RhoA, and this effect can be reversed by the proteasome inhibitor MG132. 5. **PAXIP1 - AS1 promotes pulmonary vascular remodeling through the ETS1/WIPF1/RhoA axis**: - Finally, by injecting lentiviral plasmids expressing sh - PAXIP1 - AS1 through the tail vein and using the RhoA inhibitor fasudil, the researchers verified the role of PAXIP1 - AS1 in the pathological process of PAH in vivo. - The experimental results showed that inhibiting PAXIP1 - AS1 or using fasudil can significantly reduce the right ventricular systolic pressure in the PAH model and alleviate pulmonary vascular remodeling. ### Conclusion: This study reveals the important role of PAXIP1 - AS1 in the pathological process of PAH through the ETS1/WIPF1/RhoA signaling axis and provides a new potential target for the treatment of PAH.

LncRNA PAXIP1‐AS1 fosters the pathogenesis of pulmonary arterial hypertension via ETS1/WIPF1/RhoA axis

Abstract P3004: Small Leucine-Rich Proteoglycan Asporin Represses Smooth Muscle Cell Proliferation And Regulates Pulmonary Hypertension Development

Inhibition of CXCR4 ameliorates hypoxia-induced pulmonary arterial hypertension in rats.

Abstract 18691: Asporin Attenuates Pulmonary Arterial Smooth Muscle Cell Proliferation and Regulates Pulmonary Hypertension Development

Profiling and Molecular Mechanism Analysis of Long Non-Coding RNAs and mRNAs in Pulmonary Arterial Hypertension Rat Models

Overexpressed lncRNA AC068039.4 contributes to proliferation and cell cycle progression of pulmonary artery smooth muscle cells via sponging miR-26a-5p/TRPC6 in hypoxic pulmonary arterial hypertension

Decrease in LINC00963 attenuates the progression of pulmonary arterial hypertension via microRNA‐328‐3p/profilin 1 axis

The Long Noncoding RNA LnRPT Is Regulated by PDGF-BB and Modulates the Proliferation of Pulmonary Artery Smooth Muscle Cells

MicroRNA-221-3p Promotes Pulmonary Artery Smooth Muscle Cells Proliferation by Targeting AXIN2 During Pulmonary Arterial Hypertension.

LncRNA H19 promotes the proliferation of pulmonary artery smooth muscle cells through AT1R via sponging let-7b in monocrotaline-induced pulmonary arterial hypertension

Allele-specific control of rodent and human lncRNA KMT2E-AS1 promotes hypoxic endothelial pathology in pulmonary hypertension

Astragaloside IV improves pulmonary arterial hypertension by increasing the expression of CCN1 and activating the ERK1/2 pathway

PARM1 Drives Smooth Muscle Cell Proliferation in Pulmonary Arterial Hypertension via AKT/FOXO3A Axis

Long noncoding RNA Hoxaas3 contributes to hypoxia-induced pulmonary artery smooth muscle cell proliferation

Updated perspective of EPAS1 and the role in pulmonary hypertension

Identification of JPX-RABEP1 Pair as an Immune-Related Biomarker and Therapeutic Target in Pulmonary Arterial Hypertension by Bioinformatics and Experimental Analyses

Transcriptomic profiling highlights cell proliferation in the progression of experimental pulmonary hypertension in rats

Long non-coding RNA CASC2 suppresses pulmonary artery smooth muscle cell proliferation and phenotypic switch in hypoxia-induced pulmonary hypertension

Non-Coding RNA Networks in Pulmonary Arterial Hypertension

Evaluating the Effect of Circ-Sirt1 on the Expression of SIRT1 and Its Role in Pathology of Pulmonary Hypertension

Super Enhancer-driven LncRNA UNC5B-AS1 Inhibits Inflammatory Phenotypic Transition in Smooth Muscle Cells via Lactylation Modification